Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus

Cancer

Volumn 118, Issue 19, 2012, Pages 4725-4736

  Peng, Zhen Wei ^a   Guo, Rong Ping ^a   Zhang, Yao Jun ^a   Lin, Xiao Jun ^a   Chen, Min Shan ^a   Lau, Wan Y ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

disease free survival; hepatic resection; hepatocellular carcinoma; overall survival; portal vein tumor thrombus; transcatheter arterial chemoembolization

Indexed keywords

ALPHA FETOPROTEIN; CARBOPLATIN; EPIRUBICIN; MITOMYCIN C;

ADULT; AGED; ARTICLE; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SUPERIOR MESENTERIC VEIN; SURVIVAL RATE; THROMBECTOMY; TUMOR THROMBUS; TUMOR VOLUME;

ADULT; AGED; ANALYSIS OF VARIANCE; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PORTAL VEIN; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84866489025     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26561     Document Type: Article

References (42)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
2. Bruix J, Sherman M,. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005; 42: 1208-1236.
3. Llovet JM, Brú C, Bruix J,. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19: 329-338.
4. Llovet JM, Burroughs A, Bruix J,. Hepatocellular carcinoma. Lancet. 2003; 362: 1907-1917.
5. Lai EC, Fan ST, Lo CM, et al. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg. 1995; 221: 291-298.
6. Llovet JM, Bruix J,. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003; 37: 429-442.
7. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002; 35: 1164-1171.
8. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359: 1734-1759.
9. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006; 131: 461-469.
10. Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol. 2011; 18: 413-420.
11. Kim KM, Kim JH, Park IS, et al. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol. 2009; 24: 806-814.
12. Lee HS, Kim JS, Choi IJ, et al. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer. 1997; 79: 2087-2094.
13. Ohkubo T, Yamamoto J, Sugawara Y, et al. Surgical results for hepatocellular carcinoma with macroscopic portal vein tumor thrombosis. J Am Coll Surg. 2000; 191: 657-660.
14. Wu CC, Hsieh SR, Chen JT, et al. An appraisal of liver and portal vein resection for hepatocellular carcinoma with tumor thrombi extending to portal bifurcation. Arch Surg. 2000; 135: 1273-1279.
15. Konishi M, Ryu M, Kinoshita T, et al. Surgical treatment of hepatocellular carcinoma with direct removal of the tumor thrombus in the main portal vein. Hepatogastroenterology. 2001; 48: 1421-1424.
16. Pawlik TM, Poon RT, Abdalla EK, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery. 2005; 137: 403-410.
17. Kondo K, Chijiiwa K, Kai M, et al. Surgical strategy for hepatocellular carcinoma patients with portal vein tumor thrombus based on prognostic factors. J Gastrointest Surg. 2009; 13: 1078-1083.
18. Ikai I, Hatano E, Hasegawa S, et al. Prognostic index for patients with hepatocellular carcinoma combined with tumor thrombosis in the major portal vein. J Am Coll Surg. 2006; 202: 431-438.
19. Le Treut YP, Hardwigsen J, Ananian P, et al. Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. J Gastrointest Surg. 2006; 10: 855-862.
20. Fujii T, Takayasu K, Muramatsu Y, et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol. 1993; 23: 105-109.
21. Chen XP, Qiu FZ, Wu ZD, et al. Effects of location and extension of portal vein tumor thrombus on long-Term outcomes of surgical treatment for hepatocellular carcinoma. Ann Surg Oncol. 2006; 13: 940-946.
22. Shi J, Lai EC, Li N, et al. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol. 2010; 17: 2073-2080.
23. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL Conference. European Association for the Study of the Liver. J Hepatol. 2001; 35: 421-430.
24. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649-655.
25. Shi J, Lai EC, Li N, et al. A new classification for hepatocellular carcinoma with portal vein tumor thrombus. J Hepatobiliary Pancreat Sci. 2011; 18: 74-80.
26. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
27. Sobin LH, Wittekind Ch,. TNM Classification of Malignant Tumors. Hoboken, NJ: John Wiley & Sons, 2002.
28. Lau H, Fan ST, Ng IO, et al. Long term prognosis after hepatectomy for hepatocellular carcinoma: a survival analysis of 204 consecutive patients. Cancer. 1998; 83: 2302-2311.
29. Izumi R, Shimizu K, Ii T, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology. 1994; 106: 720-727.
30. Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008; 134: 1908-1916.
31. Ng KK, Vauthey JN, Pawlik TM, et al. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol. 2005; 12: 364-373.
32. Seo DD, Lee HC, Jang MK, et al. Preoperative portal vein embolization and surgical resection in patients with hepatocellular carcinoma and small future liver remnant volume: comparison with transarterial chemoembolization. Ann Surg Oncol. 2007; 14: 3501-3509.
33. Okabe H, Beppu T, Ishiko T, et al. Preoperative portal vein embolization (PVE) for patients with hepatocellular carcinoma can improve resectability and may improve disease-free survival. J Surg Oncol. 2011 Apr 25. doi: 10.1002/jso.21928 [Epub ahead of print].
34. Yamanaka J, Saito S, Fujimoto J,. Impact of preoperative planning using virtual segmental volumetry on liver resection for hepatocellular carcinoma. World J Surg. 2007; 31: 1249-1255.
35. Jarnagin W, Chapman WC, Curley S, et al. Surgical treatment of heptaocellular carcinoma: expert consensus statement. HBP(Oxford). 2010; 12: 302-10.
36. Liau KH, Ruo L, Shia J, et al. Outcome of partial hepatectomy for large (>10 cm) hepatocellular carcinoma. Cancer. 2005; 104: 1948-1955.
37. Yang LY, Fang F, Ou DP, et al. Solitary largehepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg. 2009; 249: 118-123.
38. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334: 693-699.
39. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001; 33: 1394-1403.
40. Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007; 246: 502-511.
41. Bronowicki JP, Boudjema K, Chone L, et al. Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma. J Hepatol. 1996; 24: 293-300.
42. Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996; 111: 1018-1022.